These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12186414)

  • 1. Comparative study on salivary distribution of fluoroquinolones in rats.
    Li Q; Naora K; Hirano H; Okunishi H; Iwamoto K
    Biol Pharm Bull; 2002 Aug; 25(8):1084-9. PubMed ID: 12186414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies].
    Nagasawa M; Nakamura S; Miyazaki M; Nojima Y; Hayakawa H; Kawamura Y
    Jpn J Antibiot; 2002 Jun; 55(3):259-69. PubMed ID: 12199110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excretion of ofloxacin into saliva in rats with renal failure.
    Ding G; Naora K; Nagasako S; Hirano H; Iwamoto K
    J Pharmacol Exp Ther; 1998 Oct; 287(1):31-6. PubMed ID: 9765318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of permeability into rat cerebrospinal fluid of the quinolones: dependency on their lipophilicities.
    Ichikawa N; Naora K; Iwamoto K
    Biol Pharm Bull; 1994 Jan; 17(1):152-5. PubMed ID: 8148807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
    Zhao YL; Cai SH; Wang L; Kitaichi K; Tatsumi Y; Nadai M; Yoshizumi H; Takagi K; Takagi K; Hasegawa T
    Clin Exp Pharmacol Physiol; 2002 Mar; 29(3):167-72. PubMed ID: 11906478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat.
    Sasabe H; Kato Y; Terasaki T; Tsuji A; Sugiyama Y
    Biopharm Drug Dispos; 1999 Apr; 20(3):151-8. PubMed ID: 10211868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of 4-fluoroquinolones permeation into saliva.
    Kozjek F; Suturkova LJ; Antolic G; Grabnar I; Mrhar A
    Biopharm Drug Dispos; 1999 May; 20(4):183-91. PubMed ID: 10440793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability of phototoxic tests of fluoroquinolones in vitro.
    Zhang T; Li JL; Ma XC; Xin J; Tu ZH
    Acta Pharmacol Sin; 2003 May; 24(5):453-9. PubMed ID: 12740182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
    Kawahara S; Kamisaka K; Tada A; Nakada H; Mishima Y; Yoshimoto S; Matsuyama T; Kibata M; Nagare J
    Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary excretion of mexiletine after bolus intravenous administration in rats.
    Nagasako S; Hayashibara M; Katagiri Y; Iwamoto K
    J Pharm Pharmacol; 1992 Jan; 44(1):55-7. PubMed ID: 1350630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis].
    Sato H; Fukuda S; Inatomi M; Koide R; Uchida N; Kanda Y; Kiuchi Y; Oguchi K
    Nippon Ganka Gakkai Zasshi; 1996 Jul; 100(7):513-9. PubMed ID: 8741334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A study on the distribution of T-3262 (tosufloxacin tosilate) in salivary glands of rats using microautoradiography].
    Morihana T; Sakai H; Hayakawa H
    Jpn J Antibiot; 1989 Sep; 42(9):1868-72. PubMed ID: 2810749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats.
    Hayakawa H; Takagi K; Takano YF; Kawamura Y; Tsuji A
    J Pharm Pharmacol; 2002 Sep; 54(9):1229-36. PubMed ID: 12356277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The uptake of fluoroquinolone agent drugs by cultured human conjunctival epithelial cells and cultured SIRC rabbit corneal cells].
    Fukuda M; Yoshitake Y; Sasaki K
    Nippon Ganka Gakkai Zasshi; 1999 Aug; 103(8):576-9. PubMed ID: 10466328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dependency of salivary excretion of mexiletine on the plasma concentration in rats.
    Nagasako S; Iwamoto K; Hayashibara M; Katagiri Y
    J Pharm Pharmacol; 1993 Feb; 45(2):154-6. PubMed ID: 8095536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mandibular and parotid salivary excretion of procainamide and N-acetylprocainamide after intravenous administration of procainamide to rats.
    Watanabe J; Koyama I; Iwamoto K; Ozeki S
    J Pharm Pharmacol; 1987 Nov; 39(11):912-6. PubMed ID: 2448449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
    Fukuda H; Kawamura Y
    Jpn J Antibiot; 2002 Jun; 55(3):270-80. PubMed ID: 12199111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salivary excretion of 5-fluorouracil (5-FU). IV. Dependency of saliva/plasma concentration ratio and salivary clearance on plasma concentration of 5-FU during constant-rate intravenous infusion in rats.
    Hayashi Y; Watanabe J; Ozeki S
    J Pharmacobiodyn; 1989 Mar; 12(3):137-44. PubMed ID: 2760793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.